Publication:
Considerations for clinical trials testing radiotherapy combined with immunotherapy for metastatic disease

Simple item page
dc.contributor.coauthorVerma, Vivek
dc.contributor.coauthorHe, Kewen
dc.contributor.coauthorAbana, Chike O.
dc.contributor.coauthorBarsoumian, Hampartsaum
dc.contributor.coauthorNing, Matthew S.
dc.contributor.coauthorTang, Chad
dc.contributor.coauthorHurmuz, Pervin
dc.contributor.coauthorPuebla-Osorio, Nahum
dc.contributor.coauthorChen, Dawei
dc.contributor.coauthorTendler, Irwin
dc.contributor.coauthorComeaux, Nathan
dc.contributor.coauthorQuynh-Nhu Nguyen
dc.contributor.coauthorChang, Joe Y.
dc.contributor.coauthorWelsh, James W.
dc.contributor.departmentSchool of Medicine
dc.contributor.facultymemberYes
dc.contributor.kuauthorSezen, Duygu
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:21:47Z
dc.date.issued2021
dc.description.abstractMetastatic cancer is inherently heterogeneous, and patients with metastatic disease can experience vastly different oncologic outcomes depending on several patient-and disease specific characteristics. Designing trials for such a diverse population is challenging yet necessary to improve treatment outcomes for metastatic-previously thought to be incurable-disease. Here we review core considerations for designing and conducting clinical trials involving radiation therapy and immunotherapy for patients with metastatic cancer.
dc.description.fulltextNo
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessNO
dc.description.peerreviewstatusN/A
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipCancer Center Support (Core) Grant from the National Cancer Institute, National Institutes of Health [P30 CA016672], Supported in part by Cancer Center Support (Core) Grant P30 CA016672 from the National Cancer Institute, National Institutes of Health, to The University of Texas MD Anderson Cancer Center.
dc.description.versionN/A
dc.identifier.doi10.1016/j.semradonc.2021.02.005
dc.identifier.eissn1532-9461
dc.identifier.embargoN/A
dc.identifier.grantnoP30 CA016672
dc.identifier.issn1053-4296
dc.identifier.pubmed34090648
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85102076098
dc.identifier.urihttps://doi.org/10.1016/j.semradonc.2021.02.005
dc.identifier.urihttps://hdl.handle.net/20.500.14288/10954
dc.identifier.wos000658149000007
dc.keywordsReceiving combined immunotherapy
dc.keywordsBody radiation-therapy
dc.keywordsCost-effectiveness
dc.keywordsCTLA-4 blockade
dc.language.isoeng
dc.publisherElsevier
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofSeminars in Radiation Oncology
dc.relation.openaccessN/A
dc.rightsN/A
dc.subjectOncology
dc.subjectRadiology, nuclear medicine and medical imaging
dc.titleConsiderations for clinical trials testing radiotherapy combined with immunotherapy for metastatic disease
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorSezen, Duygu
relation.isGoalOfPublicationa9786601-9431-4553-9a46-013bb366fb87
relation.isGoalOfPublication.latestForDiscoverya9786601-9431-4553-9a46-013bb366fb87
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Collections

Publications without Fulltext